Comparing Donor Lymphocyte Infusions for Myeloid Malignancies
Posted: Tuesday, May 1, 2018
A new retrospective study confirms results of earlier work that recombinant human granulocyte colony-stimulated factor–primed donor lymphocyte infusion (gDLI) may substitute for classical DLI in effectively treating or preventing clinical or molecular relapse in multiple myeloma, with similar toxicity. At the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, a poster presentation (Abstract A123) explained the results found by the team, which was led by John De Vos, MD, PhD, of Montpellier University Hospital and the University of Montpellier, France.
According to the investigators, DLI uses the antitumoral effect of donor T and NK cells to prevent or cure relapse of lymphoid and myeloid malignancies after allogeneic stem cell transplantation. “This procedure is effective alone or associated with antitumoral chemotherapy or targeted therapy,” the researchers explained. gDLI is derived from the frozen aliquots of the initial peripheral stem cell collection.
Dr. De Vos’ team reviewed data from 140 patients treated with gDLI and classical DLI between 1998 and 2016 for various malignancies, including 36 with multiple myeloma. They reported no differences between classical DLI and gDLI in terms of response (P = .31), overall survival (P = .8), graft-versus-host disease (P =. 44), treated graft-versus-host disease (P = .78), and cause for mortality (P = .14). The results of a subgroup analysis also indicated similar outcomes with gDLI and classical DLI for lymphoid or myeloid malignancies, myeloma, or acute lymphocytic leukemia.